S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
S&P 500   3,451.24 (+0.46%)
DOW   28,348.16 (+0.49%)
QQQ   283.80 (-0.14%)
AAPL   115.49 (-1.18%)
MSFT   214.41 (-0.18%)
FB   277.28 (-0.52%)
GOOGL   1,604.78 (+1.18%)
AMZN   3,161.86 (-0.72%)
TSLA   432.62 (+2.36%)
NVDA   535.95 (-0.93%)
BABA   305.98 (-0.65%)
CGC   19.85 (+1.85%)
GE   7.66 (+4.64%)
MU   54.47 (+2.18%)
AMD   79.87 (+0.85%)
T   28.23 (+5.65%)
F   8.10 (+3.18%)
ACB   4.74 (-2.27%)
GILD   60.04 (-0.28%)
NFLX   483.37 (-1.16%)
BA   168.15 (+2.62%)
NIO   27.26 (-2.15%)
DIS   127.57 (+0.74%)
Log in
NASDAQ:CGIX

Cancer Genetics Stock Forecast, Price & News

$3.95
+0.06 (+1.54 %)
(As of 10/21/2020 04:49 PM ET)
Add
Compare
Today's Range
$3.81
Now: $3.95
$3.99
50-Day Range
$3.73
MA: $4.33
$5.75
52-Week Range
$1.92
Now: $3.95
$10.39
Volume23,149 shs
Average Volume75,538 shs
Market Capitalization$9.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Read More
Cancer Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200
Employees150

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.30 million
Cash Flow$0.11 per share
Book Value$3.52 per share

Profitability

Net Income$-6,710,000.00

Miscellaneous

Market Cap$9.12 million
Next Earnings Date11/18/2020 (Estimated)
OptionableOptionable
$3.95
+0.06 (+1.54 %)
(As of 10/21/2020 04:49 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CGIX News and Ratings via Email

Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions

How has Cancer Genetics' stock price been impacted by COVID-19 (Coronavirus)?

Cancer Genetics' stock was trading at $3.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CGIX stock has increased by 10.0% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19
.

When is Cancer Genetics' next earnings date?

Cancer Genetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 18th 2020.
View our earnings forecast for Cancer Genetics
.

How were Cancer Genetics' earnings last quarter?

Cancer Genetics Inc (NASDAQ:CGIX) announced its quarterly earnings results on Friday, August, 14th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter. The medical research company had revenue of $1.45 million for the quarter. Cancer Genetics had a negative net margin of 16.14% and a negative return on equity of 57.99%.
View Cancer Genetics' earnings history
.

Are investors shorting Cancer Genetics?

Cancer Genetics saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 27,300 shares, a decline of 40.1% from the September 15th total of 45,600 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is currently 0.0 days. Currently, 1.1% of the shares of the stock are short sold.
View Cancer Genetics' Short Interest
.

Who are some of Cancer Genetics' key competitors?

What other stocks do shareholders of Cancer Genetics own?

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the following people:
  • Mr. John A. Roberts MBA, Pres, CEO, COO & Director (Age 60)
  • Mr. Michael Glenn Miles, Chief Financial Officer
  • Mr. Michael Brian McCartney, Chief Commercial Officer
  • Mr. William Lansing Finger, Exec. VP of Precision Medicine & Biopharma Solutions
  • Dr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 56)

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $3.95.

How big of a company is Cancer Genetics?

Cancer Genetics has a market capitalization of $9.12 million and generates $7.30 million in revenue each year. Cancer Genetics employs 150 workers across the globe.

What is Cancer Genetics' official website?

The official website for Cancer Genetics is www.cancergenetics.com.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.